Labiotech.eu

News and Trends 13 Jul 2023

Gene therapy company EG 427 raises €18M

EG 427, a French biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing. The gene therapy company raised an additional €5 million ($5.6 million) in the final closing from a combination of existing investors and new family office investors, bringing the total raised in […]

July 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

New venture capital company Biovance Capital Partners launches

Bionova Capital has started a new venture capital company, Biovance Capital Partners. Bionova Capital is a healthcare-focused investor in early-stage life science companies across Europe. Founded in 2015, Bionova Capital actively manages a portfolio of five companies, two in Portugal, two in the U.K., and one in Spain. The new, independent company is fully owned […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

In Depth 12 Jul 2023

Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden

With a combined market value of over $7 billion, the life science sectors in Sweden and Denmark are thriving, with over a thousand healthcare companies being set up over the past few years. Much of this is owing to the cross-border cluster that spans regions of eastern Denmark and southern Sweden, the Medicon Valley. Racking […]

July 12, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 12 Jul 2023

ADC Therapeutics pauses clinical trial following patient deaths

ADC Therapeutics SA has announced a voluntary pause in the enrollment of new patients in the phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The action was taken by ADC Therapeutics after a recent review of aggregate data […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Pfizer kicks $25M into CellCentric

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Crossbow Therapeutics launches with $80M to target cancer

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

In Depth 11 Jul 2023

AIS Biotech: startup employs carbohydrates to fight the flu

Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […]

July 11, 2023 - 6 minutesmins - By Roohi Mariam Peter

Dr. Grégoire Stik, group leader at the Josep Carreras Leukaemia Research Institute and co-author of the study.

News and Trends 11 Jul 2023

Immune memory research could lead to next generation of epigenetic drugs

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NK:IO awarded £1.6M grant to develop NK cell therapy

NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […]

July 11, 2023 - 2 minutesmins - By Jim Cornall

Opinion 11 Jul 2023

Unlocking the power of mRNA technology

By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […]

July 11, 2023 - 4 minutesmins - By External Contributor

News and Trends 11 Jul 2023

Inhaled mRNA medicines redefine respiratory disease treatment

By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […]

July 11, 2023 - 3 minutesmins - By External Contributor

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gene therapy company EG 427 raises €18M

New venture capital company Biovance Capital Partners launches

Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden

ADC Therapeutics pauses clinical trial following patient deaths

Pfizer kicks $25M into CellCentric

Crossbow Therapeutics launches with $80M to target cancer

AIS Biotech: startup employs carbohydrates to fight the flu

Immune memory research could lead to next generation of epigenetic drugs

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NK:IO awarded £1.6M grant to develop NK cell therapy

Unlocking the power of mRNA technology

Inhaled mRNA medicines redefine respiratory disease treatment

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!